Paper · 41006098
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Jayalath VH and 32 others. Eur Urol, 2026. Cited by 10 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort. Papers, record 41006098. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41006098
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Transitional Cell | Major topic |
| Kidney Neoplasms | Major topic |
| Ureteral Neoplasms | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Neoadjuvant Therapy | |
| Male | |
| Female | |
| Aged | |
| Middle Aged | |
| Gemcitabine | |
| Deoxycytidine | |
| Treatment Outcome | |
| Cisplatin | |
| Time Factors | |
| Chemotherapy, Adjuvant | |
| Prospective Studies | |
| Disease-Free Survival |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 42,582,631 | Neoadjuvant chemotherapy in upper tract urothelial carcinoma: interpreting durable long-term outcomes in a changing treatment landscape. | https://conductscience.org/library/papers/42582631 |
Source PubMed
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,926,615 | SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers. | bioRxiv | 2026 | https://conductscience.org/library/papers/42926615 | PubMed |
| 42,807,478 | Disitamab vedotin combined with PD-1 inhibitors for postoperative adjuvant therapy in upper tract urothelial carcinoma: a retrospective exploratory case series. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42807478 | PubMed |
| 42,758,380 | Occult pT2-4 disease and postoperative loss of full-dose cisplatin eligibility in CT-staged cT≤1/cN0 upper tract urothelial carcinoma. | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/42758380 | PubMed |
| 42,604,246 | Comparative insights into upper tract urothelial carcinoma: Aligning Chinese Urological Association and European Association of Urology guidelines with clinical practice. | Asian J Urol | 2026 | https://conductscience.org/library/papers/42604246 | PubMed |
| 42,582,631 | Neoadjuvant chemotherapy in upper tract urothelial carcinoma: interpreting durable long-term outcomes in a changing treatment landscape. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42582631 | PubMed |
| 42,479,060 | Modern management of locally advanced urothelial carcinoma of the upper urinary tract. | World J Urol | 2026 | https://conductscience.org/library/papers/42479060 | PubMed |
| 42,116,836 | Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights. | Res Rep Urol | 2026 | https://conductscience.org/library/papers/42116836 | PubMed |
| 42,073,550 | Clinical Trials and Emerging Therapeutic Paradigms in Upper-Tract Urothelial Carcinoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073550 | PubMed |
| 42,016,063 | Validation of the diagnostic accuracy of a urine-based DNA methylation marker test in patients with upper urinary tract lesions. | BJUI Compass | 2026 | https://conductscience.org/library/papers/42016063 | PubMed |
| 41,807,571 | Diagnostic uncertainty of clinical T2 disease and its impact on treatment stratification in upper tract urothelial carcinoma: a multicenter retrospective study. | Sci Rep | 2026 | https://conductscience.org/library/papers/41807571 | PubMed |
1 to 10 of 11
See all 11 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41006098
GET https://conductscience.org/api/papers/v1/41006098/authors?page=2